Condition

Arterial Occlusive Diseases (1)

COVID (1)

Cardiac Arrest (1)

Idiopathic Pulmonary Fibrosis (1)

Posttraumatic Stress Disorders (1)

Overall Status

Completed (3)

Not yet recruiting (1)

Unknown status (1)

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

phase 2/phase 3 (1)

phase 3 (1)

Sponsor

Algernon Pharmaceuticals (2)

Chiba University (1)

University Hospital, Akershus (1)

University of Sao Paulo General Hospital (1)

Collaborator

Novotech (Australia) (1)

Study Documents

Informed Consent Form (1)

Intervention Type

drug (5)

device (1)

procedure (1)

Funder Type

Other (3)

Industry (2)

Study Type

Interventional (5)

Ifenprodil

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

COVID Trial in Worldwide (NP-120 (Ifenprodil))

Completed

Has Results

COVID

NP-120 (Ifenprodil)

Miami, Florida
+9 more

Dec 1, 2021

Idiopathic Pulmonary Fibrosis Trial in Australia, New Zealand (Ifenprodil)

Completed

Idiopathic Pulmonary Fibrosis

Ifenprodil

Brookvale, New South Wales, Australia
+5 more

Jul 18, 2022

PTSDs Trial in Chiba (Ifenprodil Tartrate, Placebo)

Completed

Posttraumatic Stress Disorders

Ifenprodil Tartrate
Placebo

Chiba, Chuo-ku, Japan

Department of Psychiatry, Chiba University School of Medicine Ch

Mar 17, 2019

Cardiac Arrest Trial (Morphine, Ketamine Injectable Solution, Saline 0.9%)

Not yet recruiting

Cardiac Arrest

Morphine
+2 more

(no location specified)

Jun 8, 2021

Arterial Occlusive Diseases Trial (procedure, drug, device)

Unknown status

Arterial Occlusive Diseases

Continuous peripheral sciatic nerve block
+3 more

(no location specified)

Jul 21, 2016